Reuters logo
BRIEF-Mabvax Therapeutics reports positive phase 1 results for MVT-2163 immunopet imaging agent
2017年6月14日 / 上午11点28分 / 5 个月前

BRIEF-Mabvax Therapeutics reports positive phase 1 results for MVT-2163 immunopet imaging agent

June 14 (Reuters) - Mabvax Therapeutics Holdings Inc

* Mabvax Therapeutics reports positive phase 1 results for mvt-2163 immunopet imaging agent

* Mabvax therapeutics holdings inc - mvt-2163 immunopet agent administered in combination with mvt-5873 was safe and well tolerated

* Mabvax Therapeutics holdings inc - “anticipate initiating patient dosing of our mvt-1075 radioimmunotherapy trial later this month”

* Mabvax Therapeutics - for mvt-2163, only toxicities were infusion reactions that resolved on day of injection, with some requiring supportive medication

* Mabvax Therapeutics holdings inc - results showed that mvt-5873 cold antibody pre-dose reduces liver suv facilitating detection of liver metastases

* Mabvax Therapeutics holdings inc - in addition, mvt-5873 cold antibody pre-dose does not interfere with uptake of mvt-2163 on cancer lesions Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below